ACBM
Acro Biomedical Co., Ltd. [ACBM] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ACBM Stock Summary
Top 10 Correlated ETFs
ACBM
Top 10 Correlated Stocks
ACBM
In the News
ACBM Financial details
Company Rating
Neutral
Market Cap
153.11M
Income
-15.79M
Revenue
896.5K
Book val./share
0.01
Cash/share
0
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
28 Dec 2018
P/E
-12.83
Forward P/E
-
PEG
-0.01
P/S
512.92
P/B
311.09
P/C
-
P/FCF
-1118.28
Quick Ratio
2.03
Current Ratio
4.19
Debt / Equity
0.31
LT Debt / Equity
0.01
-
-
EPS (TTM)
-0.27
EPS next Y
-
EPS next Q
-
EPS this Y
5500%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
18.62%
Revenue Q/Q
-
EPS Q/Q
0.3%
-
-
-
-
SMA20
-25.79%
SMA50
-19.43%
SMA100
-34.72%
Inst Own
-
Inst Trans
-
ROA
-1855%
ROE
-2094%
ROC
-23.93%
Gross Margin
26%
Oper. Margin
-3999%
Profit Margin
-3999%
Payout
-
Shs Outstand
60.04M
Shs Float
30.04M
-
-
-
-
Target Price
-
52W Range
2.14-4.5
52W High
-36.25%
52W Low
+27.5%
RSI
10.18
Rel Volume
0.21
Avg Volume
471
Volume
101
Perf Week
-16.39%
Perf Month
-39%
Perf Quarter
-36.25%
Perf Half Y
-36.25%
-
-
-
-
Beta
0.95672
-
-
Volatility
0.25%, 0.57%
Prev Close
0.79%
Price
2.55
Change
0.79%
ACBM Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-09-30 | 2018-09-30 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.01 | 0.17 | 0 | 0.01 | 0.02 | |
| Net income per share | 0 | 0.01 | -0.01 | 0 | -0.14 | |
| Operating cash flow per share | -0.01 | 0 | 0 | 0 | 0.01 | |
| Free cash flow per share | -0.01 | 0 | 0 | 0 | 0.01 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0.01 | 0.03 | 0.02 | 0.01 | 0.01 | |
| Tangible book value per share | 0.01 | 0.03 | 0.02 | 0.01 | 0.01 | |
| Share holders equity per share | 0.01 | 0.03 | 0.02 | 0.01 | 0.01 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 183.51M | 185.4M | 185.79M | 185.79M | 250.35M | |
| Enterprise value | 183.51M | 185.54M | 185.83M | 185.79M | 250.31M | |
| P/E ratio | -81.63K | 441.79 | -499.96 | -1.58K | -32.52 | |
| Price to sales ratio | 359.82 | 23.13 | 959.96 | 270.05 | 209.06 | |
| POCF ratio | -396.05 | -1.32K | -3.11K | -931.45 | 836.36 | |
| PFCF ratio | -396.05 | -1.32K | -3.11K | -931.45 | 836.36 | |
| P/B Ratio | 358.88 | 149.26 | 232.75 | 270.88 | 388.92 | |
| PTB ratio | 358.88 | 149.26 | 232.75 | 270.88 | 388.92 | |
| EV to sales | 359.81 | 23.15 | 960.19 | 270.06 | 209.02 | |
| Enterprise value over EBITDA | -81.63K | 359.89 | -439.58 | -1.42K | -32.53 | |
| EV to operating cash flow | -396.05 | -1.32K | -3.11K | -931.48 | 836.21 | |
| EV to free cash flow | -396.05 | -1.32K | -3.11K | -931.48 | 836.21 | |
| Earnings yield | 0 | 0 | 0 | 0 | -0.03 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.07 | 0.19 | 0.17 | 0.46 | 0.18 | |
| Debt to assets | 0.07 | 0.16 | 0.14 | 0.31 | 0.15 | |
| Net debt to EBITDA | 0.19 | 0.27 | -0.11 | -0.05 | 0.01 | |
| Current ratio | 14.83 | 6.14 | 7.88 | 3.12 | 7.71 | |
| Interest coverage | 0 | 140.75 | -213.19 | -25.67 | -1.81K | |
| Income quality | 206.11 | -0.33 | 0.16 | 1.7 | -0.04 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.1 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 4.41 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0.77 | 0 | 6.39 | |
| Graham number | 0 | 0.07 | 0.05 | 0.03 | 0.2 | |
| ROIC | 0 | 0.29 | -0.41 | -0.12 | -14.13 | |
| Return on tangible assets | 0 | 0.28 | -0.4 | -0.12 | -10.11 | |
| Graham Net | 0 | 0.01 | 0.01 | 0 | 0.01 | |
| Working capital | 511.33K | 1.24M | 767.93K | 661.17K | 614.76K | |
| Tangible asset value | 511.33K | 1.24M | 798.24K | 685.87K | 643.71K | |
| Net current asset value | 511.33K | 1.24M | 745.58K | 661.17K | 589.05K | |
| Invested capital | 0.07 | 0.11 | 0.06 | 0.04 | 0.08 | |
| Average receivables | 0 | 0 | 0 | 0 | 299K | |
| Average payables | 3.96K | 3.96K | 15.57K | 24.28K | 25.47K | |
| Average inventory | 0 | 573.3K | 1.01M | 908.28K | 469K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 182.27 | |
| Days payables outstanding | 0.48 | 0.37 | 47.95 | 17.08 | 10.19 | |
| Days of inventory on hand | 0 | 58.28 | 1.77K | 647.74 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 2 | |
| Payables turnover | 765 | 982.1 | 7.61 | 21.37 | 35.81 | |
| Inventory turnover | 0 | 6.26 | 0.21 | 0.56 | 0 | |
| ROE | 0 | 0.34 | -0.47 | -0.17 | -11.96 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0.01 | 0 | 0 | 0 | |
| Net income per share | -0.05 | -0.07 | -0.07 | -0.07 | -0.07 | |
| Operating cash flow per share | 0 | 0 | 0 | -0.01 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | -0.01 | 0 | |
| Cash per share | 0 | 0 | 0.01 | 0 | 0 | |
| Book value per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Tangible book value per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Share holders equity per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 227.48M | 264.45M | 240.17M | 255.18M | 239.57M | |
| Enterprise value | 227.33M | 264.4M | 239.85M | 255.2M | 239.58M | |
| P/E ratio | -19.01 | -17.16 | -15.28 | -15.96 | -14.93 | |
| Price to sales ratio | 0 | 442.22 | 804.58 | 0 | 0 | |
| POCF ratio | -3.52K | -4.37K | 916.21 | -737.99 | -4.5K | |
| PFCF ratio | -3.52K | -4.37K | 916.21 | -737.99 | -4.5K | |
| P/B Ratio | 400.34 | 410.82 | 373.38 | 443.88 | 486.76 | |
| PTB ratio | 400.34 | 410.82 | 373.38 | 443.88 | 486.76 | |
| EV to sales | 0 | 442.14 | 803.53 | 0 | 0 | |
| Enterprise value over EBITDA | -76.01 | -68.63 | -61.05 | -63.86 | -59.73 | |
| EV to operating cash flow | -3.52K | -4.37K | 915.01 | -738.06 | -4.5K | |
| EV to free cash flow | -3.52K | -4.37K | 915.01 | -738.06 | -4.5K | |
| Earnings yield | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.11 | 0.18 | 0.13 | 0.16 | 0.31 | |
| Debt to assets | 0.1 | 0.15 | 0.12 | 0.14 | 0.24 | |
| Net debt to EBITDA | 0.05 | 0.01 | 0.08 | -0.01 | 0 | |
| Current ratio | 10.12 | 7.71 | 10.3 | 7.7 | 4.19 | |
| Interest coverage | -16.8K | -19.07K | -18.8K | -18.94K | -8.04K | |
| Income quality | 0.02 | 0.02 | -0.07 | 0.09 | 0.01 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 4.21 | 8.44 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 6.57 | 13.16 | 0 | 0 | |
| Graham number | 0.11 | 0.13 | 0.13 | 0.12 | 0.11 | |
| ROIC | -9.82 | -7.08 | -296.32 | -6.34 | -6.79 | |
| Return on tangible assets | -4.75 | -5.06 | -5.39 | -5.97 | -6.23 | |
| Graham Net | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| Working capital | 561.95K | 614.76K | 614.03K | 545.45K | 462.47K | |
| Tangible asset value | 568.22K | 643.71K | 643.22K | 574.89K | 492.16K | |
| Net current asset value | 561.95K | 589.05K | 594.64K | 532.46K | 455.94K | |
| Invested capital | 0.01 | 0.08 | 0.07 | 0.07 | 0.06 | |
| Average receivables | 0 | 299K | 448.25K | 298.5K | 288.5K | |
| Average payables | 14.07K | 21.13K | 13.1K | 7.5K | 17.95K | |
| Average inventory | 448K | 224K | 0 | 148K | 296K | |
| Days sales outstanding | 0 | 90 | 90 | 0 | 0 | |
| Days payables outstanding | 0 | 5.26 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 1 | 1 | 0 | 0 | |
| Payables turnover | 0 | 17.1 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -5.26 | -5.99 | -6.11 | -6.95 | -8.15 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ACBM Frequently Asked Questions
What is Acro Biomedical Co., Ltd. stock symbol ?
Acro Biomedical Co., Ltd. is a US stock , located in Fishers of In and trading under the symbol ACBM
What is Acro Biomedical Co., Ltd. stock quote today ?
Acro Biomedical Co., Ltd. stock price is $2.55 today.
Is Acro Biomedical Co., Ltd. stock public?
Yes, Acro Biomedical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 471
- Market Capitalization 153.11M
- CEO Mr. Pao-Chi Chu
- Headquarters Fishers,IN,US
- IPO Date 2018-04-12
-
Website
https://acrobiomedicalco.com 
Acro Biomedical Co., Ltd. engages in developing and marketing of nutritional products. It sells cordycepin and cordyceps powder, a fungus used in traditional Chinese medicine. The company was formerly known as Killer Waves Hawaii, Inc. and changed its name to Acro Biomedical Co., Ltd. in January 2017. Acro Biomedical Co., Ltd. was incorporated in 2014 and is based in Fishers, Indiana.
